Drug Profile
Research programme: human monoclonal antibodies - Amgen/Emergent BioSolutions
Latest Information Update: 04 Sep 2006
Price :
$50
*
At a glance
- Originator Amgen; Emergent BioSolutions
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Viral infections
Most Recent Events
- 04 Sep 2006 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)
- 04 Sep 2006 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 04 Sep 2006 Discontinued - Preclinical for Viral infections in United Kingdom (unspecified route)